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Ubiquitin Signaling in Regulation 
of the Start of the Cell Cycle
Michael James Emanuele and Taylor Paige Enrico
Abstract
The small protein ubiquitin plays a vital role in virtually all aspects of cellular 
life. Among the diverse signaling outcomes associated with ubiquitination, the 
most well-established is the targeted degradation of substrates via the proteasome. 
During cell growth and proliferation, ubiquitin plays an outsized role in promoting 
progression through the cell cycle. In particular, ubiquitin-mediated degradation 
is critically important at transition points where it provides directionality and 
irreversibility to the cell cycle, which is essential for maintaining genome integ-
rity. Specifically, the boundary between G1 and S-phase is tightly regulated by 
the ubiquitin proteasome system. Notably, the G1/S boundary represents a major 
barrier to cell proliferation and is universally dysfunctional in cancer cells, allowing 
for the unbridled proliferation observed in malignancy. Numerous E3 ubiquitin 
ligases, which facilitate the ubiquitination of specific substrates, have been shown 
to control G1/S. In this chapter, we will discuss components in the ubiquitin protea-
some system that are implicated in G1/S control, how these enzymes are intercon-
nected, gaps in our current knowledge, and the potential role of these pathways in 
the cancer cycle and disease proliferation.
Keywords: cell cycle, ubiquitin, cullin RING ligase, anaphase promoting complex/
cyclosome (APC/C), G1, S-phase, SCF
1. Introduction
Progression through the cell cycle is driven by the oscillating activity of Cyclin 
Dependent Kinases (CDKs). The activity of CDKs is controlled by their binding to 
coactivator subunits termed Cyclins, as well as by CDK inhibitory proteins termed 
CKIs. The accumulation of both Cyclin and CKI proteins is tightly regulated at the 
level of transcription. In addition, Cyclin and CKI proteins are controlled at the level 
of their destruction. Remarkably, during each and every passage through the cell 
cycle, Cyclins, CKIs, and hundreds of other proteins, accumulate and are subse-
quently destroyed via a highly regulated process of programmed degradation. This 
degradation is controlled by ubiquitin.
Ubiquitin is conjugated to substrate lysines, and because ubiquitin itself contains 
seven lysine residues to which ubiquitin can be added, the repetitive addition of 
ubiquitin can result in the formation of polyubiquitin chains on substrates. These 
chains can be formed through each of the different lysines in ubiquitin, as well as 
through the amino-terminal methionine, leading to chain formations that adopt 
distinct topological features [1, 2]. The most well-characterized of these are chains 
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linked through lysine 48 in ubiquitin, so-called K48-linked ubiquitin chains, which 
target substrates to the proteasome for destruction. More recently, K11-linked chains 
were also shown to target substrates to the proteasome [3, 4]. Alternatively, ubiquitin 
chains linked through other lysines (or through methionine 1) lead to diverse signal-
ing outputs by altering protein-protein interactions, protein localization, enzyme 
activity, etc. This already complex picture is further complicated by the recent 
discovery of branched ubiquitin chains, which contain non-homogeneous lysine 
linkages. For example, branched K11/K48 chains likely represent remarkably strong 
degradative signals [5, 6].
Protein degradation through the ubiquitin proteasome system (UPS) is the 
major regulator of programmed protein destruction in human cells and plays an 
outsized role in controlling cell cycle progression [7]. Importantly, the targeted deg-
radation and/or stabilization of specific proteins at transition points (e.g. mitosis/
G1 and G1/S boundaries) promotes cell cycle progression, provides directionality 
and irreversibility to the cell cycle and maintains genome integrity [8]. Accordingly, 
numerous enzymes in the ubiquitin system have been implicated in these transition 
points.
The start of DNA replication represents a tightly controlled barrier to prolifera-
tion in normal cells. As such, nearly all of the non-dividing cells in the human body 
are arrested prior to the start of S-phase, in either G1, or in quiescence (G0), where 
they maintain the equivalent of G1-phase (2C) DNA content. In diseases of uncon-
trolled proliferation, and most notably in cancer, the S-phase boundary is per-
turbed. Thus, cancer cells are able to aberrantly enter S-phase due to a weakening 
of the G1/S border [9]. The retinoblastoma tumor suppressor pathway plays a key 
role in controlling G1/S. However, the ubiquitin system is also tightly linked to G1/S 
regulation in normal and cancer cells. Below, we will discuss the particular enzymes 
and pathways associated with ubiquitin signaling that have been implicated in 
regulating the start of S-phase.
2. Introduction to cell cycle ubiquitin ligases
2.1 Cullin RING E3 ubiquitin ligases
The RING domain family of E3 ubiquitin ligases is the largest family of E3s 
in higher eukaryotes, and in humans it is represented by several hundred unique 
enzymes and/or enzyme complexes. The cullin RING ligases (CRLs) are the larg-
est subfamily of RING E3s, encoding nearly 300 unique enzymes. The CRL E3s all 
share a common molecular architecture [10]. CRLs utilize a cullin protein back-
bone, which simultaneously binds to both an E2 ubiquitin conjugating enzyme and 
substrate, positioning E2 and substrate in close proximity, and enabling the rapid 
transfer of ubiquitin onto substrates (Figure 1A).
The human genome encodes several cullin proteins, including Cul1, Cul2, Cul3, 
Cul4A, Cul4B, Cul5, Cul7, Cul9 and the related cullin-like protein APC2. With the 
exception of APC2, each cullin is thought to assemble into a ligase with a similar 
architecture, where the amino terminus of the cullin engages targets and functions 
as a substrate targeting module, and the carboxy terminus engages the E2, function-
ing as a ubiquitin transfer module (Figure 1B). Cullin binding to substrates and 
E2-ubiquitin conjugating enzymes is indirect. Most cullins first bind to an adaptor 
protein which in turn binds to a family of substrate receptors that then recruit 
substrates for ubiquitination (Figure 1). Similarly, cullin proteins indirectly interact 
with one of two RING domain containing proteins (Roc1/Rbx1 or Roc2/Rbx2) 
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which in turn bind to E2 ubiquitin conjugating enzymes. This architecture is shared 
among all known CRL complexes.
The archetypical CRL sub-family, and one which will be discussed in greater 
detail, is the Skp1-Cul1-F-box family of CRLs. These ligases, commonly referred 
to as SCF or CRL1 ligases, utilize a family of 69 interchangeable substrate receptor 
proteins, termed F-box proteins, which designate substrates for ubiquitination and 
degradation. F-box proteins rely on an F-box domain to interact with an adaptor 
protein termed Skp1, which bridges F-box proteins to Cul1 (Figure 2). The CRL 
nomenclature dictates that specific ligase complexes are depicted with the F-Box 
protein as a superscript, following the name of the cullin complex. Thus, Cul1-based 
CRLs, in complex with the F-box substrate receptor Skp2, are designated as SCFSkp2 
or CRL1Skp2 (hereafter, Cul1-based CRL complexes will be referred to as SCF).
Importantly, substrate receptors recognize proteins for degradation based on 
short, linear sequence motifs, called degrons. Degron sequences are shared among 
the substrates of a specific E3. In addition, degrons are transferrable, and the 
addition of degron sequences to non-substrates is often sufficient to trigger their 
recognition by the E3 and subsequent ubiquitination and degradation. Also, many 
substrate receptors, although not all, require post-translation modification (e.g. 
Figure 1. 
Architecture of the cullin RING E3 ubiquitin ligases. (A) Architecture of a canonical CRL E3 ligase. (B) Boxes 
highlighting the substrate targeting (dark blue) and ubiquitin transfer (purple) modules.
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phosphorylation) of the substrate within the degron for the substrate to be recog-
nized, ubiquitinated, and degraded. Thus, the degradation of many SCF substrates 
is regulated at the level of the substrate and is a two-step process. First, the sub-
strate must be present and modified, and second, the ligase must also be available, 
thereby enabling substrate recognition and degradation. It is important to note that 
each substrate receptor can have many substrates. Furthermore, individual sub-
strates can be controlled by multiple ligases. Finally, distinct substrate adaptors can 
themselves be targeted for degradation by other E3 ligases.
The Cul1-based SCF ligases are the founding members of the CRL family. They 
were first discovered in yeast based on their role in controlling cell cycle progres-
sion. Their discovery grew out of gain-of-function screens performed by Elledge 
and colleagues, which identified suppressors of the yeast cell cycle mutant Cdc4. 
This screen uncovered a new protein, whose mRNA and protein levels oscillated 
during the cell cycle. Moreover, the amino acid sequence of this new protein 
included a Cyclin homology domain, similar to that found in the previously iden-
tified Cyclins A, B, D, and E. Thus, this new protein was named Cyclin F [11]. 
Significantly, Cyclin F contained a domain with sequence similarity to Cdc4, which 
they named the F-box domain. They found that the F-box domains in Cyclin F and 
Cdc4 were essential for tethering both proteins to the ubiquitin machinery via bind-
ing to Skp1 [12]. Shortly thereafter, the Harper lab, in collaboration with Elledge, as 
well as the Deshaies lab, showed that SCF complexes could trigger the ubiquitina-
tion and degradation of the yeast CDK inhibitor Sic1. Moreover, these studies dem-
onstrated that the F-box protein Cdc4 preferentially bound to the phosphorylated 
version of Sic1, thereby triggering its ubiquitination and degradation [13, 14].
2.2 The Anaphase Promoting Complex/Cyclosome
Like other E3 ubiquitin ligases, the Anaphase Promoting Complex/Cyclosome 
(APC/C) plays an important role in protein degradation. APC/C regulates the 
Figure 2. 
Architecture of the SCF ligase. (A) Example of an SCF-type ligase bound to a short linear degron sequence 
motif in a substrate. (B) Example of an SCF-type ligase bound to phosphorylation-dependent degron in a 
substrate.
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ubiquitination and degradation of the CDK activator proteins Cyclin A and Cyclin 
B, in addition to many other cell cycle regulated proteins. As such, it is a core 
component of the cell cycle oscillator. As its name suggests, the APC/C is activated 
in metaphase of mitosis, during which time it triggers the ubiquitination and 
degradation of numerous proteins including two critical substrates, Cyclin B and 
securin, thereby “promoting anaphase” and mitotic exit. In addition to its essential 
function in mitosis, APC/C also plays an evolutionarily conserved role in G1-phase. 
The APC/C remains active throughout G1, where in contrast to its role in promoting 
progression through mitosis, the APC/C restrains progression through G1-phase 
into S-phase [17], and is not turned off until immediately prior to the start of DNA 
replication [15, 16]. Significantly, APC/C inactivation at the G1/S boundary is 
required for the start of S-phase.
Similar to the CRLs discussed above, the APC/C has both a cullin-like subunit 
(APC2) and a RING subunit (APC11). However, the APC/C is significantly dif-
ferent than the CRL ligases discussed above. Notably, the APC/C is composed of 
18 polypeptide subunits and is a remarkable 1.2 mDa in size (Figure 3). The cullin 
subunit, APC2, is the most divergent of the cullins, and lacks features that are 
common among other cullin proteins. For example, while other cullin proteins are 
post-translationally modified and activated by the small, ubiquitin-like protein 
Nedd8, this process is not thought to be involved in APC/C activity.
The APC/C utilizes either of two substrate receptors during somatic cell cycles. 
First, during mitosis, the APC/C binds to the substrate receptor/coactivator Cdc20, 
which brings Cyclin B and Securin to the APC/C for ubiquitination. Immediately 
following mitotic exit, APC/C shifts to using a second substrate adaptor, the Cdc20-
related protein Cdh1/Fzr1 (hereafter referred to as Cdh1). The Cdh1-bound form 
of APC/C remains active throughout G1-phase and targets a myriad of cell cycle 
regulators for degradation, including proteins involved in transcription, nucleotide 
metabolism, and CDK activation. Thus, it is APC/CCdh1 that must be inactivated 
prior to the beginning of S-phase. Both Cdc20 and Cdh1 recognize substrates 
via short, linear degron motifs in substrates. The most well-characterized and 
widespread of these degron motifs among APC/C substrates are the D-box (amino 
acid sequence R-X-X-L, where X is any amino acid) and the KEN box (amino acid 
sequence K-E-N). Thus, the ability of Cdc20 or Cdh1 to recruit substrate proteins 
harboring D- or KEN-box motifs to the APC/C is required for the subsequent 
ubiquitination and destruction of APC/C targets.
Like the SCF, the APC/C was identified by virtue of its key role in cell cycle. It 
had been known that the key CDK activator Cyclin B is controlled by degradation, 
Figure 3. 
Architecture of the APC/C ubiquitin ligase. The color scheme is the same as above for SCF ligases. Several 
proteins are specifically shown, including the cullin subunit APC2, the RING subunit APC11, and the substrate 
receptor Cdh1. Note that there are many more components.
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and that both the accumulation and degradation of Cyclin B play a vital role in cell 
cycles, particularly in early frog embryos [18]. In 1995, the regulator of Cyclin B 
was discovered by the Kirschner and Hershko labs, who named it the Anaphase 
Promoting Complex and Cyclosome, respectively [19, 20].
3. Role and regulation of SCF ligases in G1/S control
The SCF complexes can assemble from any one of 69 well-established substrate 
receptor F-box proteins in humans. A subset of SCF ubiquitin ligase complexes have 
been directly implicated in G1/S control. Here we will discuss the role of each of 
these distinct complexes and/or substrate receptors, aspects of their regulation and 
function, and their contribution to G1 progression and S-phase initiation.
3.1 CDC4
The yeast specific Cell Division Control gene/protein 4, called Cdc4, was one 
of the original cell cycle mutants identified by Hartwell and colleagues, who later 
received the Nobel Prize for the analysis of cell cycle in budding yeast. They showed 
that Cdc4 mutant yeast arrest at the G1/S boundary, prior to the start of DNA rep-
lication [21]. However, it took another 20 years for the essential molecular function 
of Cdc4 in promoting cell cycle progression to become clear, and in doing so, laid 
the foundation for the discovery of CRL ligases.
As the analysis of cell cycle control became increasingly popular in the late 1980s 
and early 1990s, researchers revisited the role of Cdc4. Nasmyth and colleagues 
showed that the budding yeast Cdc4 mutants, which arrest before the start of DNA 
replication when grown at their restrictive temperature, lack appreciable CDK 
activity [22]. Interestingly, cell cycle arrest is caused by an inability of Cdc4 mutant 
cells to downregulate the yeast CKI Sic1, which normally decreases at the end of G1. 
The decrease in Sic1 allows the increase in CDK activity needed to enter S-phase. 
Thus, yeast cells cannot enter S-phase when Cdc4 is inactivated [11].
As discussed above, Cdc4 is an F-box protein that binds to Sic1, promoting its 
ubiquitination by the SCFCdc4 complex. The mechanism by which Cdc4 recognizes 
Sic1 to promote its degradation provides a clear example of the interplay between 
phosphorylation and ubiquitination cascades. Interestingly, Sic1 must first be 
phosphorylated by Cyclin-CDK complexes, and this phosphorylation enables the 
binding of Cdc4 to Sic1 [13, 14]. Once phosphorylated and bound to Cdc4, Sic1 is 
recruited to the SCF complex for ubiquitination (Figure 4). Thus, CDKs promote 
their own activity at the G1/S boundary by triggering the degradation of their inhibi-
tor, Sic1 (Figure 4B). This implies a positive feedback loop in control of S-phase 
entry. While the mechanism by which Cdc4 controls G1/S is largely attributed to its 
role in destroying Sic1, Cdc4 has also been linked to other cell cycle regulators and 
proteins involved in proliferative control. Cdc4 substrates include numerous proteins 
involved in MAPK signaling that mediate cell cycle arrest in response to pheromone 
[23–26], the replication regulator Cdc6 [27], the sirtuin deacetylase Hst3 [28], as 
well as proteins involved in sister chromatid cohesion [29], regulation of calcineurin 
[30], and mating-type switching [31]. Because Cdc4 has many substrates, it plays a 
complex and multi-faceted role in yeast cell cycle, among other processes.
3.2 Skp2
The F-box protein Skp2 has been well-characterized in human cells and plays 
an important role in the G1/S transition. Similar to Cdc4, Skp2 plays a key role 
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in regulating CDKs by promoting the destruction of CKI proteins. In particular, 
Skp2 plays an important role in promoting the destruction of the human CKI 
p27 [32, 33]. Moreover, the ubiquitination of p27 by SCFSkp2 requires that it first 
be phosphorylated by CDK, and this subsequently targets p27 for destruction, 
suggesting a similar positive feedback loop in G1/S regulation (Figure 5) [34]. 
Similarly, SCFSkp2 can target two other CKI proteins for degradation. These are p21 
and p57, both of which are degraded in proliferating cells going through the cell 
cycle [35, 36], although p21 is also degraded by a second Cul4-based CRL ligase 
once DNA replication has begun [37]. Finally, Skp2 has been linked to the degra-
dation of the retinoblastoma related protein RBL2/p130 [38, 39]. Like RB, RBL2/
p130 restrains the activity of a cell cycle E2F transcription factor that promotes 
proliferation and cell cycle progression.
As might be expected, Due to its role in promoting S-phase via the degradation 
of CKIs, Skp2 is often overexpressed in cancers, which likely contributes to cancer 
cell proliferation [40]. Chemical approaches aimed at identifying Skp2 inhibitors 
have been undertaken, with some success [41, 42].
In addition to its role in regulating several target proteins, including the CKIs 
discussed above, Skp2 plays a complex and more paradoxical role in regulating 
proliferation. The Myc transcription factor is a potent oncogene, that is activated 
in many cancers and which drives proliferation through myriad mechanisms [43]. 
Myc is ubiquitinated by Skp2 [44, 45]. However, remarkably, the ubiquitination 
and degradation of Myc catalyzed by SCFSkp2 triggers an increase in Myc activity. 
This is consistent with prior work implicating proteolysis in the activation of several 
transcription factors in both yeast and humans [46]. Accordingly, a stable allele of 
Myc that cannot be ubiquitinated is more abundant, localized to target promoters, 
Figure 4. 
SCFCdc4 promotes S-phase entry in yeast by triggering the degradation of the CKI Sic1. (A) Binding between 
Sic1 and Cdc4 is triggered by phosphorylation of Sic1, which then promotes Sic1 ubiquitination and 
degradation. (B) A positive feedback loop between Cdc4, Sic1 and CDK promotes S-phase entry.
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but it is less active [47]. Taken together, these studies paint a complex picture of the 
role of Skp2 in cell cycle progression but suggest an important role in proliferation 
and likely in the pathogenesis of cancer.
Interestingly, Skp2 is itself regulated by ubiquitin mediated proteolysis. Skp2 is 
targeted for degradation by the Anaphase Promoting Complex/Cyclosome during 
G1-phase of the cell cycle [48, 49]. The degradation of p27 requires the upregulation 
of Skp2. This degradation would presumably occur after Skp2 levels accumulate, 
following the inactivation of APC/C, which occurs in late G1. That is, APC/C 
inactivation should lead to an increase in Skp2 levels, since Skp2 would no longer 
be degraded. Only then could Skp2 promote the degradation of p27. However, this 
complex order of events remains unclear and has not yet been tested directly. Since 
the abundance of CKIs, like p27, should prevent the activation of G1/S CDKs, this 
also implies that APC/C inactivation precedes CDK activation. As discussed below, 
this too remains unknown, and recent evidence suggests, in fact, that APC/C 
inactivation occurs after CDK activation in G1 [16].
In addition to its regulation by ubiquitination, Skp2 is also regulated by phos-
phorylation. This phosphorylation is mediated, in part, by the oncogenic kinase 
AKT [50]. Notably, AKT kinase activity is cell cycle regulated, and begins to 
increase in late G1-phase [51]. Skp2 phosphorylation by AKT increases Skp2 stabil-
ity and alters its localization. Surprisingly, SCFSkp2 also ubiquitinates AKT, and 
enhances AKT activation [52]. The degradation of p27 and activation of AKT and 
Myc, by Skp2, are likely to play an important role in tumor biology and treatment. 
The degradation of p27, a negative cell cycle regulator, creates an environment more 
permissive to proliferation because cells lacking p27 can progress through the cell 
cycle more rapidly. In addition, the activation of AKT and Myc could contribute 
significantly to cancer cell cycles.
Figure 5. 
SCFSkp2 promotes S-phase entry in humans by triggering the degradation of the CKI p27. (A) Binding between 
p27 and Skp2 is triggered by phosphorylation of p27, which then promotes p27 ubiquitination and degradation. 
(B) A positive feedback loop between Skp2, p27 and CDK promotes S-phase entry.
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3.3 Cyclin F/FBX01
The eponymous Cyclin F is the founding member of the F-box family of E3 
ubiquitin ligases [11, 12, 53]. Cyclin F is unique among F-box proteins in that it 
contains a Cyclin homology domain, similar to canonical Cyclins that bind and 
activate CDKs. However, unlike those other Cyclins, Cyclin F neither binds nor 
activates a CDK [53]. In addition, Cyclin F levels oscillate strongly throughout 
the cell cycle, and this is the result of both changes in its transcription and deg-
radation. Notably, Cyclin F is the only F-box protein that was identified as cell 
cycle regulated in all global studies of human cell cycle transcriptional dynamics 
[54]. Accordingly, Cyclin F knockout mouse embryonic fibroblasts showed a 
strong defect in cell cycle entry following synchronization in quiescence [55]. 
Nevertheless, despite this strong cell cycle phenotype and being the first described 
F-box protein in higher eukaryotes, Cyclin F went a long time without having a 
bona fide substrate.
The first two substrates described for Cyclin F were the centrosome protein 
CP110 and the spindle associated, mitotic phospho-protein NUSAP1 [56, 57], 
further supporting a role in cell cycle, and pointing to a function in organizing the 
microtubule cytoskeleton. In addition, Cyclin F regulates the RRM2 subunit of 
ribonucleotide reductase [58], histone mRNA stem loop binding protein SLBP [59], 
and the DNA replication protein Cdc6 [60], highlighting a role in S-phase progres-
sion and genome stability.
Importantly, Cyclin F regulates the degradation of Cdh1, the substrate recep-
tor for the APC/C ubiquitin ligase (Figure 6). APC/CCdh1 is activated throughout 
G1-phase and its inactivation is critical for S-phase entry. Thus, Cyclin F-mediated 
degradation of Cdh1 was shown to play a critical role in entry into S-phase [61]. 
Interestingly, in addition to targeting the APC/C substrate receptor Cdh1 for deg-
radation, Cyclin F is also a substrate of APC/C in mitosis and early G1-phase [61]. 
Thus, Cyclin F exists in a double-negative feedback loop with APC/C, where it is a 
substrate in mitosis and early G1, and then the regulator of Cdh1 degradation in late 
G1 and S-phase (Figure 6).
Like Skp2, Cyclin F is also phosphorylated by the oncogenic kinase AKT [62]. 
Similar to Skp2, the phosphorylation of Cyclin F by AKT leads to a significant 
increase in Cyclin F stability. Phosphorylation by AKT enhances Cyclin F assembly 
into SCF ligase complexes. Thus, phosphorylation contributes to the switch in 
Cyclin F, from being an APC/C substrate to being capable of targeting for Cdh1 deg-
radation in late G1-phase [62]. The tight regulation of Cyclin F throughout the cell 
cycle, its substrates, phosphorylation by AKT, and regulation by other E3s, point to 
its critical role in cell cycle progression. Moreover, these results suggest that Cyclin 
F is a key regulatory node mediating the interaction between AKT-dependent 
growth factor signaling and the core cell cycle machinery.
3.4 FBXW7/FBW7/FBXO30
The SCFFbxw7 ubiquitin ligase (also called SCFFBW7 or SCFFBXO30) is the most 
tightly linked to cancer proliferation of all SCF-type E3s [63]. Fbxw7, is highly 
mutated in human cancers, and exhibits both truncating mutations throughout 
its gene body, as well as “hotspot” point mutations in its substrate binding motif. 
Interestingly, while Fbxw7 is generally considered a tumor suppressor [64], 
“hotspot” mutations are more commonly found in oncogenes, such as the common 
G12V mutation recurrently observed in oncogenic K-Ras in many human malignan-
cies. SCFFbxw7 promotes cell cycle progression by regulating the degradation of 
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Cyclin E, the key activator of CDK2 at the G1/S boundary [63, 65–67]. In addition, 
Fbxw7 regulates the ubiquitination and destruction of numerous other pro-prolif-
erative and cancer associated proteins, including Myc [68, 69], Notch [70, 71] and 
Jun [72].
Similar to other SCF ligases, the SCFFbxw7 ligase recognizes substrates through 
phospho-degron motifs, with the most well characterized being that on Cyclin 
E. The phosphorylation of Cyclin E, by CDK2 or GSK3, can promote the degrada-
tion of Cyclin E by enhancing its binding to Fbxw7 [64, 66, 67, 73]. In addition, 
Fbxw7 homo-dimerizes, and this dimerization plays an important role in its ability 
to target substrates for degradation [74].
Figure 6. 
SCFCyclin F and APC/C constitute a double-negative feedback loop. (A) APC/CCdh1 targets Cyclin F for 
degradation in late mitosis and early G1. (B) SCFCyclin F targets Cdh1 for degradation in late G1 and S-phase. 
(C) Together, this suggests a temporally ordered, double negative feedback loop that promotes S-phase entry.
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3.5 EMI1/Fbx05
Emi1 is a cell cycle regulated F-box domain-containing protein. However, Emi1 
is unique among F-box proteins in that it has no known substrates, despite the fact 
that it binds tightly to the SCF adaptor Skp1. Emi1 is instead a key regulator of the 
cell cycle E3 ligase APC/C [75].
Many studies have demonstrated the potent and extensive role that Emi1 plays in 
inhibiting APC/C. Emi1 acts as a pseudo-substrate for APC/C, blocking the binding 
and ubiquitination of substrates [76]. In addition, Emi1 can alter the binding of the 
APC/C E2 ubiquitin conjugating enzymes, providing additional layers of regulation 
[77–79].
The association of Emi1 with S-phase entry is complex. Based largely on gain-
of-function approaches, Emi1 was shown capable of inhibiting APC/C at the G1/S 
boundary and promoting S-phase entry [80]. This was fitting, since Emi1 abun-
dance is controlled by the E2F family of transcription factors, which are activated 
in mid G1 and promote G1/S [80]. However, loss of Rca1, the fly version of Emi1, 
leads to an accumulation of cells in later stages of the cell cycle, not at G1/S [81]. 
Similarly, the loss of Emi1 in human cells was reported to induce the reactivation 
of APC/C during S and G2-phase, and to induce DNA re-replication as a result of 
the degradation of proteins which normally restrain licensing of replication origins 
[82, 83]. However, consistent with early gain-of-function studies, recent single 
cell approaches suggest that Emi1 contributes to the kinetics of APC/C inactiva-
tion at G1/S, and that Emi1 locks APC/C in an off state once S-phase begins [16]. 
Surprisingly, Emi1 might also be a substrate of the APC/C [84]. If Emi1 is a sub-
strate of APC/C, this implies that Emi1 could be ubiquitinated by APC/C in early 
G1, and that it later accumulates as an inhibitor to inactivate APC/C and promote 
S-phase entry, much like Cyclin F [84]. This adds to our understanding of Emi1 
degradation, wherein previous studies had shown it was degraded in mitosis by the 
SCFbTRCP ubiquitin ligase [85, 86]. It will be important in the future to determine if 
altering the ubiquitination and degradation of Emi1 by APC/C accelerates progres-
sion through G1/S and to determine how this is coordinated with other SCF ligases 
that regulate G1/S.
4. Involvement of APC/C in G1/S
An extensive body of evidence has defined the role of APC/CCdh1 in G1/S control 
[17]. Early studies in yeast showed that Cyclin proteolysis starts in late mitosis but 
then persists as cells continue through G1-phase [87]. In addition, yeast cells lacking 
Cdh1 are defective at arresting in G1-phase. Similar results have been observed across 
all eukaryotes in which loss of Cdh1 has been studied, including worms [88, 89], flies 
[90], chickens [91], mice [92] and humans [16, 61, 93]. The loss of Cdh1 accelerates 
progression through G0/G1 and promotes the start of S-phase. In addition, cells 
lacking Cdh1 are universally defective in G0/G1 arrest [17]. Accordingly, single allelic 
loss of Cdh1, the APC/C substrate receptor/coactivator in G0/G1-phase, is sufficient 
to cause tumors in mice [94]. Since the APC/C controls the stability of many dozens 
of substrates, it is unlikely that any one provides the basis for how cells enter S-phase 
in the absence of G1 APC/C function. Instead, it is more likely that the concerted 
upregulation of many cell cycle drivers together provides an explanation for the vital 
role of APC/C in restraining G1/S. Nevertheless, the APC/C is among a small group 
of key signaling molecules that prevent entry into S-phase of the cell cycle. These 
regulators include the retinoblastoma tumor suppressor and its related proteins p107 
and p130, as well as the CDK inhibitors p21, p27 and p57.
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Myriad mechanisms account for the inactivation of APC/C at the G1/S bound-
ary, some of which were discussed above. This includes the degradation of Cdh1 
by SCFCyclin F and perhaps by the APC/C itself [61, 95]. The APC/C E2 enzymes, 
Ube2S and Ube2C, are unstable proteins and are also APC/C substrates [4, 96]. The 
substrate receptor Cdh1 is subject to CDK dependent phosphorylation, preventing 
its association with the APC/C and likely affecting its localization [89, 97–101]. 
Finally, accumulation of Emi1 is controlled by E2F, contributing to APC/C inhibi-
tion [16, 80, 84].
5. Distilling the complexity of ubiquitination in G1/S
The interconnected web of enzymes, substrates, and pathways discussed above 
paints a complicated picture of G1/S control. Remarkably, our understanding of 
the role of ubiquitin ligases in S-phase entry pales in comparison to studies per-
formed on parallel kinase signaling cascades that converge on the E2F transcription 
factor. In quiescent and early G1 cells, E2F activity is repressed by the retinoblas-
toma tumor suppressor (RB), as well as the RB-like proteins P130 and P107. The 
phosphorylation of RB, first by Cyclin D-CDK4/6, and then by Cyclin E-Cdk2, 
inactivates RB and derepresses E2F. This derepression, in turn, triggers the tran-
scriptional upregulation of many genes needed for S-phase entry.
How then do the pathways described above fit together with each other, and 
with the canonical CDK-RB-E2F pathway? We propose that multiple pathways 
act coordinately to promote the start of DNA replication. The most well-studied 
of these is the RB-E2F pathway, which promotes S-phase entry by promoting the 
expression of numerous cell cycle genes. In parallel, ubiquitin signaling pathways 
that control the degradation of numerous cell cycle proteins coordinate entry into 
S-phase. First, SCFSkp2 must be active and able to promote the degradation of CKI 
proteins. Second, SCFFbw7 must be inactive or otherwise unable to ubiquitinate 
its substrates Cyclin E and Myc, which accumulate to promote cell cycle. Third, 
SCFCyclin F must be available to trigger the degradation of Cdh1 and help promote 
the inactivation of APC/C. And finally, the APC/C must be inactivated, by 
Cyclin F and other pathways, allowing for the accumulation of cell cycle proteins 
(many of which are transcribed by E2F), to promote S-phase entry (Figure 7). 
It is notable that Cyclin F and Skp2, as well as many other cell cycle proteins, are 
downregulated by APC/C. Altogether, this suggests that aberrant APC/C inacti-
vation could promote cancer cell cycles. Accordingly, single allelic loss of Cdh1 
causes cancer in mice [94]. How APC/C might be inactivated in cancer remains 
an open question of significant importance that has only recently begun to be 
studied [17].
Upstream of these regulators are myriad kinase signaling cascades. These kinase 
cascades include, for example, the phosphorylation of RB by CDK4/6 and also 
CDK2; phosphorylation of Cyclin F and Skp2 by AKT; and, phosphorylation of 
Myc and Cyclin E, thereby marking them for degradation by Fbw7. Significantly, 
we hypothesize that these pathways control S-phase entry by globally remodeling 
the protein landscape either through changes in gene expression or protein degrada-
tion. The activity of CDK2, CDK4/6 and AKT is dysregulated in many cancers. This 
suggests that dysregulated cell cycle transcription, as well as dysregulated cell cycle 
ubiquitination, likely contributes to a weakening of the G1/S boundary and uncon-
trolled cancer cell cycles.
Testing this hypothesis and determining how these pathways are integrated 
remains an important question for future study. Determining the order of and 
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integration between these pathways is also critical. For example, recent live 
imaging studies demonstrated that CDK2 becomes active in mid-G1, several 
hours before APC/C is turned off. Moreover, these studies indicate that APC/C 
inactivation occurs at nearly the same time as DNA replication [16]. What is 
unclear is how Emi1, Cyclin F, and Skp2 accumulate at this time, as these pro-
teins have never before been studied together in the same experimental system. 
In addition, the overwhelming majority of studies that have interrogated the 
kinetics of their accumulation have relied on bulk biochemical measurements 
(immunoblots) in synchronized cells. While informative, these studies would 
be better undertaken in asynchronous cells using either immunofluorescence 
or live cell reporters. Further, CDK2 activity begins to increase many hours 
before the inactivation of APC/C. It is therefore unknown how APC/C remains 
active into late G1-phase and is protected from CDK-dependent inactivation. 
Resolving these important questions will provide insight regarding how cells 
breach the G1/S boundary during the homeostatic cell cycles that occur during 
organismal development and growth, or in response to cell damage or wound-
ing. Importantly, the G1/S boundary is universally dysfunctional in cancer and 
is the target of therapeutic interventions in the treatment of disease. Therefore, 
unraveling the complex pathways and mechanisms by which the ubiquitin system 
contributes to G1/S will shed light on both the etiology and treatment of cancer 
in the future.
Acknowledgements
Special thanks go to the Emanuele laboratory for feedback. Work in the 
Emanuele lab is supported by start-up funds from the University Cancer 
Research Fund and The National Institute of General Medical Sciences (NIH; 
R01GM120309).
Conflict of interest
The authors declare no competing conflicts of interest.
Figure 7. 
Overview of ubiquitin signaling pathways involved in G1/S. A subset of substrates are shown. Note that the 
APC/C controls the stability of several dozen substrate proteins during late mitosis and early G1.
Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease
14
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Michael James Emanuele* and Taylor Paige Enrico
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
*Address all correspondence to: emanuele@email.unc.edu
15
Ubiquitin Signaling in Regulation of the Start of the Cell Cycle
DOI: http://dx.doi.org/10.5772/intechopen.82874
References
[1] Williamson A, Werner A, Rape M.  
The colossus of ubiquitylation: 
Decrypting a cellular code. Molecular 
Cell. 2013;49:591-600
[2] Yau R, Rape M. The increasing 
complexity of the ubiquitin code. 
Nature Cell Biology. 2016;18:579-586
[3] Matsumoto ML, Wickliffe KE, Dong 
KC, Yu C, Bosanac I, Bustos D, et al. 
K11-linked polyubiquitination in cell 
cycle control revealed by a K11 linkage-
specific antibody. Molecular Cell. 
2010;39:477-484
[4] Williamson A, Wickliffe KE, 
Mellone BG, Song L, Karpen GH, Rape 
M. Identification of a physiological 
E2 module for the human anaphase-
promoting complex. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2009;106:18213-18218
[5] Yau RG, Doerner K, Castellanos ER,  
Haakonsen DL, Werner A, Wang N,  
et al. Assembly and function of 
heterotypic ubiquitin chains in cell-
cycle and protein quality control. Cell. 
2017;0:1-16
[6] Meyer H-J, Rape M. Enhanced 
protein degradation by branched 
ubiquitin chains. Cell. 2014;157:910-921
[7] Zhang J, Wan L, Dai X, Sun Y, 
Wei W. Functional characterization 
of anaphase promoting complex/
Cyclosome (APC/C) E3 ubiquitin 
ligases in tumorigenesis. Biochimica et 
Biophysica Acta. 2014;1845:277-293
[8] Potapova TA, Daum JR, Pittman BD,  
Hudson JR, Jones TN, Satinover DL, 
et al. The reversibility of mitotic 
exit in vertebrate cells. Nature. 
2006;440:954-958
[9] Sherr CJ, Bartek J. Cell cycle–targeted 
Cancer therapies. Annual Review of 
Cancer Biology. 2017;1:41-57
[10] Petroski MD, Deshaies RJ. Function 
and regulation of cullin-RING ubiquitin 
ligases. Nature Reviews. Molecular Cell 
Biology. 2005;6:9-20
[11] Bai C, Richman R, Elledge SJ.  
Human cyclin F. The EMBO Journal. 
1994;13:6087-6098
[12] Bai C, Sen P, Hofmann K, Ma L,  
Goebl M, Harper JW, et al. SKP1 
connects cell cycle regulators to the 
ubiquitin proteolysis machinery 
through a novel motif, the F-box. Cell. 
1996;86:263-274
[13] Skowyra D, Craig KL, Tyers M,  
Elledge SJ, Harper JW. F-box 
proteins are receptors that recruit 
phosphorylated substrates to the 
SCF ubiquitin-ligase complex. Cell. 
1997;91:209-219
[14] Feldman RM, Correll CC, Kaplan 
KB, Deshaies RJ. A complex of Cdc4p, 
Skp1p, and Cdc53p/cullin catalyzes 
ubiquitination of the phosphorylated 
CDK inhibitor Sic1p. Cell. 
1997;91:221-230
[15] Brandeis M, Hunt T. The proteolysis 
of mitotic cyclins in mammalian cells 
persists from the end of mitosis until 
the onset of S phase. The EMBO Journal. 
1996;15:5280-5289
[16] Cappell SD, Chung M, Jaimovich A,  
Spencer SL, Meyer T. Irreversible 
APCCdh1 inactivation underlies the 
point of No return for cell-cycle entry. 
Cell. 2016;166:167-180
[17] Kernan J, Bonacci T, Emanuele 
MJ. Who guards the guardian? 
Mechanisms that restrain APC/C during 
the cell cycle. Biochimica et Biophysica 
Acta (BBA)—Molecular Cell Research. 
2018
[18] Murray AW, Solomon MJ, Kirschner 
MW. The role of cyclin synthesis and 
degradation in the control of maturation 
Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease
16
promoting factor activity. Nature. 
1989;339:280-286
[19] Sudakin V, Ganoth D, Dahan A, 
Heller H, Hershko J, Luca FC, et al. The 
cyclosome, a large complex containing 
cyclin-selective ubiquitin ligase activity, 
targets cyclins for destruction at the 
end of mitosis. Molecular Biology of the 
Cell. 1995;6:185-197
[20] King RW, Peters JM, Tugendreich 
S, Rolfe M, Hieter P, Kirschner MW. A 
20S complex containing CDC27 and 
CDC16 catalyzes the mitosis-specific 
conjugation of ubiquitin to cyclin B.  
Cell. 1995;81:279-288
[21] Hartwell LH, Culotti J, Pringle JR,  
Reid BJ. Genetic control of the cell 
division cycle in yeast. Science. 
1974;183:46-51
[22] Schwob E, Böhm T, Mendenhall 
MD, Nasmyth K. The B-type cyclin 
kinase inhibitor p40SIC1 controls the 
G1 to S transition in S cerevisiae. Cell. 
1994;79:233-244
[23] Cappell SD, Baker R, Skowyra 
D, Dohlman HG. Systematic analysis 
of essential genes reveals important 
regulators of G protein signaling. 
Molecular Cell. 2010
[24] Chou S, Huang L, Liu H. Fus3-
regulated Tec1 degradation through 
SCFCdc4 determines MAPK signaling 
specificity during mating in yeast. Cell. 
2004
[25] Vendrell A, Martánez-Pastor M, 
González-Novo A, Pascual-Ahuir A, 
Sinclair DA, Proft M, et al. Sir2 histone 
deacetylase prevents programmed cell 
death caused by sustained activation of 
the Hog1 stress-activated protein kinase. 
EMBO Reports. 2011
[26] Hurst JH, Dohlman HG. Dynamic 
ubiquitination of the mitogen-activated 
protein kinase kinase (MAPKK) Ste7 
determines mitogen-activated protein 
kinase (MAPK) specificity. The Journal 
of Biological Chemistry. 2013
[27] Drury LS, Perkins G, Diffley JFX.  
The Cdc4/34/53 pathway targets Cdc6p 
for proteolysis in budding yeast. The 
EMBO Journal. 1997
[28] Edenberg ER, Vashisht AA, Topacio 
BR, Wohlschlegel JA, Toczyski DP. Hst3 
is turned over by a replication stress-
responsive SCFCdc4 phospho-degron. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2014;111:5962-5967
[29] Lyons NA, Morgan DO. Cdk1-
dependent destruction of Eco1 prevents 
cohesion establishment after S phase. 
Molecular Cell. 2011
[30] Kishi T, Ikeda A, Nagao R, Koyama 
N. The SCFCdc4 ubiquitin ligase 
regulates calcineurin signaling through 
degradation of phosphorylated Rcn1, an 
inhibitor of calcineurin. Proceedings of 
the National Academy of Sciences of the 
United States of America. 2007
[31] Liu Q, Larsen B, Ricicova M, Orlicky 
S, Tekotte H, Tang X, et al. SCFCdc4 
enables mating type switching in yeast 
by Cyclin-dependent kinase-mediated 
elimination of the Ash1 transcriptional 
repressor. Molecular and Cellular 
Biology. 2011
[32] Pagano M, Tam SW, Theodoras 
AM, Beer-Romero P, Del Sal G, Chau V, 
et al. Role of the ubiquitin-proteasome 
pathway in regulating abundance of the 
cyclin-dependent kinase inhibitor p27. 
Science. 1995;269:682-685
[33] Carrano AC, Eytan E, Hershko 
A, Pagano M. SKP2 is required for 
ubiquitin-mediated degradation of the 
CDK inhibitor p27. Nature Cell Biology. 
1999;1:193-199
[34] Montagnoli A, Fiore F, Eytan E, 
Carrano AC, Draetta GF, Hershko A, 
et al. Ubiquitination of p27 is regulated 
17
Ubiquitin Signaling in Regulation of the Start of the Cell Cycle
DOI: http://dx.doi.org/10.5772/intechopen.82874
by Cdk-dependent phosphorylation and 
trimeric complex formation. Genes & 
Development. 1999
[35] Bornstein G, Bloom J, Sitry-Shevah 
D, Nakayama K, Pagano M, Hershko 
A. Role of the SCFSkp2 ubiquitin ligase 
in the degradation of p21Cip1 in S phase. 
The Journal of Biological Chemistry. 
2003
[36] Kamura T, Hara T, Kotoshiba 
S, Yada M, Ishida N, Imaki H, et al. 
Degradation of p57Kip2 mediated by 
SCFSkp2-dependent ubiquitylation. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2003
[37] Abbas T, Sivaprasad U, Terai 
K, Amador V, Pagano M, Dutta 
A. PCNA-dependent regulation of 
p21 ubiquitylation and degradation 
via the CRL4Cdt2 ubiquitin ligase 
complex. Genes & Development. 
2008;22:2496-2506
[38] Tedesco D, Lukas J, Reed SI. The 
pRb-related protein p130 is regulated 
by phosphorylation-dependent 
proteolysis via the protein-ubiquitin 
ligase SCFSkp2. Genes & Development. 
2002;16:2946-2957
[39] Bhattacharya S, Garriga J, 
Calbó J, Yong T, Haines DS, Graña 
X. SKP2 associates with p130 and 
accelerates p130 ubiquitylation and 
degradation in human cells. Oncogene. 
2003;22:2443-2451
[40] Zheng N, Zhou Q, Wang Z, Wei 
W. Recent advances in SCF ubiquitin 
ligase complex: Clinical implications. 
Biochimica et Biophysica Acta. 
2016;1866:12-22
[41] Chan C-H, Morrow JK, Li 
C-F, Gao Y, Jin G, Moten A, et al. 
Pharmacological inactivation of Skp2 
SCF ubiquitin ligase restricts cancer 
stem cell traits and cancer progression. 
Cell. 2013;154:556-568
[42] Wu L, Grigoryan AV, Li Y, Hao B, 
Pagano M, Cardozo TJ. Specific small 
molecule inhibitors of Skp2-mediated 
p27 degradation. Chemistry & Biology. 
2012;19:1515-1524
[43] Tansey WP. Mammalian MYC 
proteins and cancer. New Journal of 
Science. 2014;2014:1-27
[44] Von Der Lehr N, Johansson S, Wu S, 
Bahram F, Castell A, Cetinkaya C, et al. 
The F-box protein Skp2 participates 
in c-Myc proteosomal degradation 
and acts as a cofactor for c-Myc-
regulated transcription. Molecular Cell. 
2003;11:1189-1200
[45] Kim SY, Herbst A, Tworkowski KA, 
Salghetti SE, Tansey WP. Skp2 regulates 
Myc protein stability and activity. 
Molecular Cell. 2003;11:1177-1188
[46] Geng F, Wenzel S, Tansey WP.  
Ubiquitin and proteasomes in 
transcription. Annual Review of 
Biochemistry. 2012;81:177-201
[47] Jaenicke LA, von Eyss B, Carstensen 
A, Wolf E, Xu W, Greifenberg AK, 
et al. Ubiquitin-dependent turnover 
of MYC antagonizes MYC/PAF1C 
complex accumulation to drive 
transcriptional elongation. Molecular 
Cell. 2016;61:54-67
[48] Bashir T, Dorrello NV, Amador V, 
Guardavaccaro D, Pagano M. Control 
of the SCFSkp2–Cks1 ubiquitin ligase 
by the APC/CCdh1 ubiquitin ligase. 
Nature. 2004;428:190-193
[49] Wei W, Ayad NG, Wan Y, Zhang 
G-J, Kirschner MW, Kaelin WG.  
Degradation of the SCF component 
Skp2 in cell-cycle phase G1 by the 
anaphase-promoting complex. Nature. 
2004;428:194-198
[50] Gao D, Inuzuka H, Tseng A, Chin 
RY, Toker A, Wei W. Phosphorylation by 
Akt1 promotes cytoplasmic localization 
of Skp2 and impairs APCCdh1-mediated 
Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease
18
Skp2 destruction. Nature Cell Biology. 
2009;11:397-408
[51] Liu P, Begley M, Michowski W, 
Inuzuka H, Ginzberg M, Gao D, et al. 
Cell-cycle-regulated activation of 
Akt kinase by phosphorylation at its 
carboxyl terminus. Nature. 2014
[52] Chan C-H, Li C-F, Yang W-L, Gao 
Y, Lee S-W, Feng Z, et al. The Skp2-SCF 
E3 ligase regulates Akt ubiquitination, 
glycolysis, herceptin sensitivity, and 
tumorigenesis. Cell. 2012;149:1098-1111
[53] D’Angiolella V, Esencay M, Pagano 
M. A cyclin without cyclin-dependent 
kinases: Cyclin F controls genome 
stability through ubiquitin-mediated 
proteolysis. Trends in Cell Biology. 
2013;23:135-140
[54] Fischer M, Grossmann P, Padi M,  
DeCaprio JA. Integration of TP53, 
DREAM, MMB-FOXM1 and RB-E2F 
target gene analyses identifies cell cycle 
gene regulatory networks. Nucleic Acids 
Research. 2016;44:6070-6086
[55] Tetzlaff MT, Bai C, Finegold M, 
Harper JW, Mahon KA, Stephen J, 
et al. Cyclin F disruption compromises 
placental development and affects 
normal cell cycle execution. Molecular 
and Cellular Biology. 2004;24:2487-2498
[56] D’Angiolella V, Donato V, 
Vijayakumar S, Saraf A, Florens L, 
Washburn MP, et al. SCF Cyclin F 
controls centrosome homeostasis 
and mitotic fidelity through CP110 
degradation. Nature. 2010;466:138-142
[57] Emanuele MJ, Elia AEH, Xu Q, 
Thoma CR, Izhar L, Leng Y, et al. Global 
identification of modular cullin-RING 
ligase substrates. Cell. 2011;147:459-474
[58] D’Angiolella V, Donato V, Forrester 
FM, Jeong Y, Pellacani C, Kudo Y, et al. 
Cyclin F-mediated degradation of 
ribonucleotide reductase M2 controls 
genome integrity and DNA repair. Cell. 
2012;149:1023-1034
[59] Dankert JF, Rona G, Clijsters L, 
Geter P, Skaar JR, Bermudez-Hernandez 
K, et al. Cyclin F-mediated degradation 
of SLBP limits H2AX accumulation and 
apoptosis upon genotoxic stress in G2. 
Molecular Cell. 2016
[60] Walter D, Hoffmann S, Komseli 
E-S, Rappsilber J, Gorgoulis V, Sørensen 
CS. SCFCyclin F-dependent degradation 
of CDC6 suppresses DNA re-replication. 
Nature Communications. 2016;7:10530
[61] Choudhury R, Bonacci T, Arceci 
A, Lahiri D, Mills CA, Kernan JL, 
et al. APC/C and SCF(cyclin F) 
constitute a reciprocal feedback circuit 
controlling S-phase entry. Cell Reports. 
2016;16:3359-3372
[62] Choudhury R, Bonacci T, Wang 
X, Truong A, Arceci A, Zhang Y, et al. 
The E3 ubiquitin ligase SCF(Cyclin 
F) transmits AKT signaling to the 
cell-cycle machinery. Cell Reports. 
2017;20:3212-3222
[63] Welcker M, Clurman BE. FBW7 
ubiquitin ligase: A tumour suppressor at 
the crossroads of cell division, growth 
and differentiation. Nature Reviews. 
Cancer. 2008;8:83-93
[64] Koepp DM, Schaefer LK, Ye X, 
Keyomarsi K, Chu C, Harper JW, 
et al. Phosphorylation-dependent 
ubiquitination of cyclin E by the 
SCFFbw7 ubiquitin ligase. Science. 
2001;294:173-177
[65] Strohmaier H, Spruck CH, Kaiser 
P, Won KA, Strohmaier H, Reed 
SI. Archipelago regulates Cyclin E levels 
in Drosophila and is mutated in human 
cancer cell lines. Nature. 2001
[66] Strohmaier H, Spruck CH, Kaiser P, 
Won KA, Sangfelt O, Reed SI. Human 
F-box protein hCdc4 targets cyclin E for 
19
Ubiquitin Signaling in Regulation of the Start of the Cell Cycle
DOI: http://dx.doi.org/10.5772/intechopen.82874
proteolysis and is mutated in a breast 
cancer cell line. Nature. 2001
[67] Welcker M, Singer J, Loeb KR, Grim 
J, Bloecher A, Gurien-West M, et al. 
Multisite phosphorylation by Cdk2 and 
GSK3 controls cyclin E degradation. 
Molecular Cell. 2003
[68] Welcker M, Orian A, Jin J, 
Grim JE, Harper JW, Eisenman RN, 
et al. The FBW7 tumor supressor 
regulates glycogen synthase kinase 3 
phosphorylation-dependent c-Myc 
protein degradation. PNAS. 2004
[69] Yada M, Hatakeyama S, Kamura 
T, Nishiyama M, Tsunematsu R, Imaki 
H, et al. Phosphorylation-dependent 
degradation of c-Myc is mediated by the 
F-box protein Fbw7. The EMBO Journal. 
2004
[70] Wu G, Lyapina S, Das I, Li J, 
Gurney M, Pauley A, et al. SEL-10 is an 
inhibitor of notch signaling that targets 
notch for ubiquitin-mediated protein 
degradation. Molecular and Cellular 
Biology. 2001
[71] Gupta-Rossi N, Le Bail O, Gonen H, 
Brou C, Logeat F, Six E, et al. Functional 
interaction between SEL-10, an F-box 
protein, and the nuclear form of 
activated Notch1 receptor. The Journal 
of Biological Chemistry. 2001
[72] Nateri AS, Riera-Sans L, Da Costa 
C, Behrens A. The ubiquitin ligase 
SCFFbw7 antagonizes apoptotic JNK 
signaling. Science. 2004:80
[73] Won KA, Reed SI. Activation of 
cyclin E/CDK2 is coupled to site-specific 
autophosphorylation and ubiquitin-
dependent degradation of cyclin E. The 
EMBO Journal. 1996
[74] Welcker M, Larimore EA, Swanger 
J, Bengoechea-Alonso MT,  
Grim JE, Ericsson J, et al. Fbw7 
dimerization determines the 
specificity and robustness of substrate 
degradation. Genes & Development. 
2013;27:2531-2536
[75] Reimann JDR, Freed E, Hsu 
JY, Kramer ER, Peters JM, Jackson 
PK. Emi1 is a mitotic regulator that 
interacts with Cdc20 and inhibits the 
anaphase promoting complex. Cell. 
2001;105:645-655
[76] Miller JJ, Summers MK, Hansen 
DV, Nachury MV, Lehman NL, Loktev 
A, et al. Emi1 stably binds and inhibits 
the anaphase-promoting complex/
cyclosome as a pseudosubstrate 
inhibitor. Genes & Development. 
2006
[77] Frye JJ, Brown NG, Petzold G, 
Watson ER, Grace CRR, Nourse A, 
et al. Electron microscopy structure 
of human APC/C(CDH1)-EMI1 
reveals multimodal mechanism of E3 
ligase shutdown. Nature Structural & 
Molecular Biology. 2013;20:827-835
[78] Wang W, Kirschner MW. Emi1 
preferentially inhibits ubiquitin chain 
elongation by the anaphase-promoting 
complex. Nature Cell Biology. 
2013;15:797-806
[79] Chang L, Zhang Z, Yang J, 
McLaughlin SH, Barford D. Atomic 
structure of the APC/C and its 
mechanism of protein ubiquitination. 
Nature. 2015
[80] Hsu JY, Reimann JDR, Sørensen CS, 
Lukas J, Jackson PK. E2F-dependent 
accumulation of hEmi1 regulates S 
phase entry by inhibiting APC(Cdh1). 
Nature Cell Biology. 2002;4:358-366
[81] Grosskortenhaus R, Sprenger 
F. Rca1 inhibits APC-Cdh1(Fzr) and is 
required to prevent cyclin degradation 
in G2, Dev. Cell. 2002;2:29-40
[82] Machida YJ, Dutta A. The APC/C 
inhibitor, Emi1, is essential for 
Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease
20
prevention of rereplication. Genes & 
Development. 2007;21:184-194
[83] DiFiore B, Pines J. Defining the 
role of Emi1 in the DNA replication-
segregation cycle. Chromosoma. 
2008;117:333-338
[84] Cappell SD, Mark KG, Garbett D,  
Pack LR, Rape M, Meyer T. EMI1 
switches from being a substrate to an 
inhibitor of APC/CCDH1 to start the 
cell cycle. Nature. 2018
[85] Margottin-Goguet F, Hsu JY, Loktev 
A, Hsieh HM, Reimann JDR, Jackson 
PK. Prophase destruction of Emi1 by 
the SCFβTrCP/Slimbubiquitin ligase 
activates the anaphase promoting 
complex to allow progression beyond 
prometaphase. Developmental Cell. 
2003
[86] Guardavaccaro D, Kudo Y, Boulaire 
J, Barchi M, Busino L, Donzelli M, 
et al. Control of meiotic and mitotic 
progression by the F box protein β-Trcp1 
in vivo. Developmental Cell. 2003
[87] Amon A, Irniger S, Nasmyth K.  
Closing the cell cycle circle in yeast: 
G2 cyclin proteolysis initiated at 
mitosis persists until the activation 
of G1 cyclins in the next cycle. Cell. 
1994;77:1037-1050
[88] Fay DS, Keenan S, Han M. fzr-1 
and lin-35/Rb function redundantly to 
control cell proliferation in C elegans 
as revealed by a nonbiased synthetic 
screen. Genes & Development. 
2002;16:503-517
[89] The I, Ruijtenberg S, Bouchet BP, 
Cristobal A, Prinsen MBW, van Mourik 
T, et al. Rb and FZR1/Cdh1 determine 
CDK4/6-cyclin D requirement in C 
elegans and human cancer cells. Nature 
Communications. 2015;6:5906
[90] Buttitta LA, Katzaroff AJ, Edgar 
BA. A robust cell cycle control 
mechanism limits E2F-induced 
proliferation of terminally differentiated 
cells in vivo. The Journal of Cell Biology. 
2010;189:981-996
[91] Sudo T, Ota Y, Kotani S, Nakao M, 
Takami Y, Takeda S, et al. Activation 
of Cdh1-dependent APC is required 
for G1 cell cycle arrest and DNA 
damage-induced G2 checkpoint in 
vertebrate cells. The EMBO Journal. 
2001;20:6499-6508
[92] Sigl R, Wandke C, Rauch V, Kirk J, 
Hunt T, Geley S. Loss of the mammalian 
APC/C activator FZR1 shortens G1 and 
lengthens S phase but has little effect 
on exit from mitosis. Journal of Cell 
Science. 2009;122:4208-4217
[93] Yuan X, Srividhya J, De Luca T, Lee 
J-HE, Pomerening JR. Uncovering the 
role of APC-Cdh1 in generating the 
dynamics of S-phase onset. Molecular 
Biology of the Cell. 2014;25:441-456
[94] García-Higuera I, Manchado E, 
Dubus P, Cañamero M, Méndez J, 
Moreno S, et al. Genomic stability and 
tumour suppression by the APC/C 
cofactor Cdh1. Nature Cell Biology. 
2008;10:802-811
[95] Listovsky T, Oren YS, Yudkovsky Y, 
Mahbubani HM, Weiss AM, Lebendiker 
M, et al. Mammalian Cdh1/Fzr mediates 
its own degradation. The EMBO Journal. 
2004;23:1619-1626
[96] Rape M, Kirschner MW.  
Autonomous regulation of the 
anaphase-promoting complex couples 
mitosis to S-phase entry. Nature. 
2004;432:588-595
[97] Kramer ER, Scheuringer N, 
Podtelejnikov AV, Mann M, Peters JM.  
Mitotic regulation of the APC activator 
proteins CDC20 and CDH1. Molecular 
Biology of the Cell. 2000;11:1555-1569
[98] Hall MC, Warren EN, Borchers CH.  
Multi-kinase phosphorylation of 
the APC/C activator Cdh1 revealed 
21
Ubiquitin Signaling in Regulation of the Start of the Cell Cycle
DOI: http://dx.doi.org/10.5772/intechopen.82874
by mass spectrometry. Cell Cycle. 
2004;3:1278-1284
[99]  Höckner S, Neumann-arnold 
L, Seufert W. Dual control by Cdk1 
phosphorylation of the budding yeast 
APC/C ubiquitin ligase activator 
Cdh1. Molecular Biology of the Cell. 
2016;27:2198-2212
[100] Zachariae W, Schwab M, 
Nasmyth K, Seufert W. Control 
of cyclin ubiquitination by CDK-
regulated binding of Hct1 to the 
anaphase promoting complex. Science. 
1998;282:1721-1724
[101] Jaquenoud M, Van Drogen F, 
Peter M. Cell cycle-dependent nuclear 
export of Cdh1p may contribute to the 
inactivation of APC/CCdh1. The EMBO 
Journal. 2002;21:6515-6526
